Загрузка...
Next Generation Therapeutics for the Treatment of Myelofibrosis
Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to acute leukemia. JAK inhibitors are the only approved therapy for myelofibrosis and have been successful in reducing spleen and sympt...
Сохранить в:
| Опубликовано в: : | Cells |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8146033/ https://ncbi.nlm.nih.gov/pubmed/33925695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10051034 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|